TA181 | Pemetrexed for the first-line treatment of non-small-cell lung cancer |
TA182 | Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention |
TA183 | Topotecan for the treatment of recurrent and stage IVB cervical cancer |
TA185 | Trabectedin for the treatment of advanced soft tissue sarcoma |
TA186 | Certolizumab pegol for the treatment of rheumatoid arthritis |
TA189 | Sorafenib for the treatment of advanced hepatocellular carcinoma |
TA190 | Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
TA191 | Capecitabine for the treatment of advanced gastric cancer |
TA192 | Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
TA193 | Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
TA196 | Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
TA197 | Dronedarone for the treatment of non-permanent atrial fibrillation |
TA198 | Tocilizumab for the treatment of rheumatoid arthritis |
TA201 | Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years |
TA202 | Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
TA203 | Liraglutide for the treatment of type 2 diabetes mellitus |
TA204 | Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
TA205 | Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
TA208 | Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
TA211 | Prucalopride for the treatment of chronic constipation in women |
TA212 | Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
TA213 | Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years |
TA214 | Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer |
TA215 | Pazopanib for the first-line treatment of advanced renal cell carcinoma |
TA216 | Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
TA218 | Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
TA219 | Everolimus for the second-line treatment of advanced renal cell carcinoma |
TA220 | Golimumab for the treatment of psoriatic arthritis |
TA221 | Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
TA222 | Trabectedin for the treatment of relapsed ovarian cancer |
TA225 | Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
TA226 | Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
TA227 | Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
TA229 | Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
TA230 | Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
TA232 | Retigabine for the adjunctive treatment of partial onset seizures in epilepsy |
TA233 | Golimumab for the treatment of ankylosing spondylitis |
TA234 | Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs |
TA235 | Mifamurtide for the treatment of osteosarcoma |
TA236 | Ticagrelor for the treatment of acute coronary syndromes |
TA237 | Ranibizumab for the treatment of diabetic macular oedema |
TA238 | Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
TA239 | Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
TA244 | Roflumilast for the management of severe chronic obstructive pulmonary disease |
TA245 | Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
TA248 | Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes |
TA249 | Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
TA250 | Eribulin for the treatment of locally advanced or metastatic breast cancer |
TA252 | Telaprevir for the treatment of genotype 1 chronic hepatitis C |
TA253 | Boceprevir for the treatment of genotype 1 chronic hepatitis C |
TA254 | Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |
TA255 | Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen |
TA256 | Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
TA258 | Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
TA259 | Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen |
TA260 | Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
TA261 | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
TA263 | Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
TA264 | Alteplase for treating acute ischaemic stroke |
TA266 | Mannitol dry powder for inhalation for treating cystic fibrosis |
TA267 | Ivabradine for treating chronic heart failure |
TA268 | Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
TA269 | Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma |
TA271 | Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy |
TA272 | Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract |
TA275 | Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
TA282 | Pirfenidone for treating idiopathic pulmonary fibrosis |
TA283 | Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
TA284 | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
TA285 | Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
TA287 | Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
TA288 | Dapagliflozin in combination therapy for treating type 2 diabetes |
TA289 | Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis |
TA290 | Mirabegron for treating symptoms of overactive bladder |
TA291 | Pegloticase for treating severe debilitating chronic tophaceous gout |
TA292 | Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
TA293 | Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura |
TA294 | Aflibercept solution for injection for treating wet age-related macular degeneration |
TA295 | Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy |
TA296 | Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene |
TA297 | Ocriplasmin for treating vitreomacular traction |
TA298 | Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
TA299 | Bosutinib for previously treated chronic myeloid leukaemia |
TA303 | Teriflunomide for treating relapsing–remitting multiple sclerosis |
TA305 | Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
TA306 | Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma |
TA307 | Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
TA308 | Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
TA309 | Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer |
TA310 | Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
TA311 | Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
TA312 | Alemtuzumab for treating relapsing-remitting multiple sclerosis |
TA313 | Ustekinumab for treating active psoriatic arthritis |
TA315 | Canagliflozin in combination therapy for treating type 2 diabetes |
TA316 | Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen |
TA318 | Lubiprostone for treating chronic idiopathic constipation |
TA319 | Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
TA320 | Dimethyl fumarate for treating relapsing-remitting multiple sclerosis |
TA321 | Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
TA322 | Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |